Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.46 USD | +6.09% | +16.61% | +59.69% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- Low profitability weakens the company.
- With an enterprise value anticipated at 4.77 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+59.69% | 1.39B | B- | ||
-27.67% | 9.87B | A- | ||
-17.30% | 2.74B | C | ||
-11.15% | 2.24B | - | B- | |
-22.32% | 1.63B | C+ | ||
+23.58% | 771M | C- | ||
-1.31% | 760M | C+ | ||
-28.57% | 516M | C- | ||
+5.37% | 310M | - | - | |
+12.46% | 219M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MRVI Stock
- Ratings Maravai LifeSciences Holdings, Inc.